S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. - Wikidata - wikimedia - TriplyDB

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.

http://www.wikidata.org/entity/Q33426501

about

Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis Definitive concurrent chemoradiotherapy with S-1 and cisplatin in elderly esophageal squamous cell carcinoma patients.Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma Future directions in esophageal cancer therapy.Chemotherapy for advanced gastric cancer.Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.

P2860

Q33433129-DF75F9FA-1FB9-40CD-A744-87F9A8805348 Q33571196-036173EC-ED54-43BF-A734-DBD5DA546D69 Q33889328-565E7439-EEA9-476F-8794-0946E68133E7 Q33913820-930A6ADD-DD4A-43EE-9C11-852C2C4DB68C Q37747378-60579F2C-C172-40CF-B594-C6FD18BF893C Q38604012-8EC47837-E1DE-4EBC-A15A-45FEC15784C9 Q38645852-CF5B3DB9-F96A-4278-B83F-F21C6997F6B1 Q42370438-A24C3366-5E7F-4133-AA71-37C53993B2C0

P2860

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.

http://www.wikidata.org/entity/Q33426501

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

S-1 plus cisplatin versus fluo ...... inoma patients: a pilot study.

@ast

S-1 plus cisplatin versus fluo ...... inoma patients: a pilot study.

@en

type

label

S-1 plus cisplatin versus fluo ...... inoma patients: a pilot study.

@ast

S-1 plus cisplatin versus fluo ...... inoma patients: a pilot study.

@en

prefLabel

S-1 plus cisplatin versus fluo ...... inoma patients: a pilot study.

@ast

S-1 plus cisplatin versus fluo ...... inoma patients: a pilot study.

@en

P1433

Q33426501-2CFC046F-AA5C-4722-81F7-CC0B80C1240E

P1476

Q33426501-6A1BA537-C1AC-4A8C-81E5-55921D74A21B

P2093

Q33426501-17EEB75C-4B06-42E6-8E49-50C2B817D95E

Q33426501-3497D71B-2FF6-4D28-9C36-3F379AAEA0C6

Q33426501-4C4D8B0F-CCB8-4F6E-B974-C1F61365D313

Q33426501-5FEE8830-94A6-47B1-AD13-C581A0121F38

Q33426501-6EBCBF2F-8590-4F57-A16B-4919EB655692

Q33426501-74819B2D-417A-4AC1-9752-35594B653128

Q33426501-8A42EE5A-FA7C-410D-A9E6-FD22682042F0

Q33426501-93C7E5DA-99C4-4CBD-91D3-C4F97A2A951C

Q33426501-A2E45C4E-3F4E-4165-9BC7-D762F0A74129

Q33426501-C22BB2A6-521D-47A1-B05C-703506D3274B

P2860

Q33426501-1A9C1BBF-F8C5-43EB-B934-DA8D5DC7FC79

Q33426501-36A0575A-CD08-42A2-964C-C11B2DED68F0

Q33426501-3CA6C073-7AB0-4D7C-BD6A-ADACA878970E

Q33426501-3E1436E9-B366-4214-AB6B-30C623511183

Q33426501-6108F704-97F5-45AA-9679-A15D9742120A

Q33426501-78B3A20A-FDB5-4C1E-8161-478D2D2A7C69

Q33426501-7B8AFD63-B8EC-4914-B45B-E065AE607E27

Q33426501-7F457AF6-CB0C-4E0C-B734-151DF9B26F11

Q33426501-837A518B-BFA1-41F9-98A0-777EA68D1880

Q33426501-89477743-FD78-43D7-B912-96834E2AF198

P304

Q33426501-CA17F3AA-8527-4331-9A73-62E4ABF31468

P31

Q33426501-7EC765F9-7457-4884-B835-E1690CD902EA

P356

Q33426501-230270AA-4CEC-49B8-9B61-ABA0E787BB41

P407

Q33426501-051E9985-4356-4C81-A194-7FA067F4FBEA

P433

Q33426501-D7420A81-8928-4C17-956D-5069C5866D40

P478

Q33426501-44B5E4B7-EE79-4F8C-BB6E-262BA1189EAD

P577

Q33426501-46263F4D-F1F4-411A-A95F-3F7BC0981B55

P5875

Q33426501-025E76E0-5609-400A-B256-C59CDD4FA984

P698

Q33426501-C03C214A-F564-4EB5-B604-E91B3FB9C40E

P921

Q33426501-FF4C339E-FFC6-4D7F-BA40-574DFEC39749

P932

Q33426501-8E41A0FB-7A0E-4C7D-B208-80D3B8EBDF18

P356

ONCOTARGET.5959

P1433

P1476

S-1 plus cisplatin versus fluo ...... inoma patients: a pilot study.

@en

P2093

Guo Ping Sun

http://www.w3.org/2001/XMLSchema#string

He Long Zhang

http://www.w3.org/2001/XMLSchema#string

Hui Shan Lu

http://www.w3.org/2001/XMLSchema#string

Jian Ming Xu

http://www.w3.org/2001/XMLSchema#string

Jie Jun Wang

http://www.w3.org/2001/XMLSchema#string

Jun Tian Zhou

http://www.w3.org/2001/XMLSchema#string

Mei Zuo Zhong

http://www.w3.org/2001/XMLSchema#string

Miao Zhen Qiu

http://www.w3.org/2001/XMLSchema#string

Rui Hua Xu

http://www.w3.org/2001/XMLSchema#string

Shi Ying Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.

Clinical evidence for three distinct gastric cancer subtypes: time for a new approach.

S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.

S-1 in gastric cancer: a comprehensive review.

P304

35107-35115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.5959

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282582578

http://www.w3.org/2001/XMLSchema#string

P698

26439700

http://www.w3.org/2001/XMLSchema#string

P921

P932

4741513

http://www.w3.org/2001/XMLSchema#string